ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies AP3 identified mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment to overcome resistance through sensitization to ACR-368 via ultra-low dose gemcitabine WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or ...